Invasive aspergillosis in organ transplant recipients: New issues in epidemiologic characteristics, diagnosis, and management

Medical Mycology

Volumn 43, Issue SUPPL.1, 2005, Pages

  Singh, N ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Fungal infection; Transplants

Indexed keywords

ALEMTUZUMAB; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN A; ECHINOCANDIN; IMMUNOSUPPRESSIVE AGENT; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VORICONAZOLE;

ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG POTENTIATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; MORTALITY; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; RECIPIENT; RISK REDUCTION; T CELL DEPLETION; TREATMENT PLANNING;

ASPERGILLOSIS; HUMANS; ORGAN TRANSPLANTATION;

ASPERGILLUS;

EID: 22844440804     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/13693780500051984     Document Type: Article

References (27)

1. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine 1999; 78: 123-138.
2. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplantation 2004; 4: 636-643.
3. Kwak EJ, Husain S, Obman A, et al. Efficacy of galactomannan antigen using Platelia® Aspergillus enzyme immunoassay for the diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 2004; 42: 435-438.
4. Husain S, Kwak EJ, Obman A, et al. Prospective assessment of Platelia™ Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant 2004; 4: 796-802.
5. Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52.
6. Lugardon K, Chasserot-Golaz S, Kieffer A-E, et al. Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide. J Biol Chem 2001; 276: 35875-35882.
7. High KP. The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation 1994; 57: 1689-1700.
8. Steinbach WJ, Singh N, Miller JL, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and non-transplant patients. Antimicrob Agents Chemother 2004 (in press).
9. Murase N, Metes D, Zeevi A, et al. Immunomonitoring of liver transplant recipients treated with tolerance-enhancing regimen of immunosuppression. Am J Transplant 2004; 8: 40.
10. Koffron JCC, Dixler I, Kulik L, et al. Campath 1-H (alemtuzumab) induction in liver transplantation: a single center experience. Am J Transplant 2004; 8: 267.
11. Shapiro R, Tan HP, Basu A, et al. Campath 1-H preconditioning and tacrolimus monotherapy with subsequent weaning in renal transplant recipients. Am J Transplant 2004; 8: 405.
12. Almyroudis S, Jaffe D, Sepkowitz KA, et al. Risk factors for late invasive aspergillosis (IA) after allogeneic, stem cell transplantation. 43rd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 14-17, 2003.
13. Stynen D, Goris A, Sarfati J, Latge JP. A new sensitive sandwich ELISA to detect galactofuran in patients with invasive aspergillosis. J Clin Microbiol 1995; 33: 497-500.
14. Maertens JJ, Verhaegan J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillsois. J Clin Microbiol 1999; 37: 3223-3228.
15. Verweij PE, Stynen D, Rijs AMMM, et al. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol 1995; 33: 1912-1914.
16. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Ped Infect Dis J 1996; 15: 232-237.
17. Bretagne, S, Costa J-M, Bart-Delabesse E, et al. Comparison of serum galactomannan antigen detection and competitive polymerase chain reaction for diagnosing invasive aspergillosis. Clin Infect Dis 1998; 26: 1407-1412.
18. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-1610.
19. Machetti M, Feasi M, Mordini N, et al. Comparison of an enzyme immunoassay and a latex agglutination system for the diagnosis of invasive aspergillosis in bone marrow transplant recipients. Bone Marrow Transplant 1998; 21: 917-921.
20. Ulusakarya A, Chachaty E, Vantelon J-M, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1: 111-116.
21. Fortun J, Martin-Davila P, Alvarez ME, et al. The Ramon y Cajal Hospital's liver Transplant Group. Aspergillus antigenemia sandwich-enzyme immunoassay test as a serodiagnostic method for invasive aspergillosis in liver transplant recipients. Transplantation 2001; 71: 145-149.
22. Cameron ML, Granger DL, Matthews TJ, Weinberg JB. Human immunodeficiency virus (HIV)-infected human blood monocytes and peritoneal macrophages have reduced anticryptococcal activity whereas HIV-infected alveolar macrophages retain normal activity. J Infect Dis 1994; 170: 60-70.
23. Linden PK. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin Pharmacother 2003; 4: 2099-2110.
24. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Eng J Med 2002; 347: 408-415.
25. Hachem RY, Raad II, Afif CM, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy. 40th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000.
26. Kontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003; 51: 313-316.
27. Fox DS, Heitman J. Good fungi gone bad: the corruption of calcineurin. BioEssays 2003; 24: 894-903.